Macrophages derived from human induced pluripotent stem cells (iPSCs) have the potential
to enable the development of cell-based therapies for numerous disease conditions. We …

Soft tissue defects are a common clinical challenge mostly caused by trauma, congenital
anomalies and oncological surgery. Current soft tissue reconstruction options include …

A lack of stratification methods in patients with amyotrophic lateral sclerosis (ALS) is likely
implicated in therapeutic failures. Regional diversities and pathophysiological abnormalities …

During the last years, several strategies have been made to obtain mature erythrocytes or
red blood cells (RBC) from the bone marrow or umbilical cord blood (UCB). However, UCB …

Cell reprogramming is a revolutionized biotechnology that offers a powerful tool to engineer
cell fate and function for regenerative medicine, disease modeling, drug discovery, and …

Background Induced pluripotent stem cell (iPSC)-derived cell therapies are an interesting
new area in the field of regenerative medicine. One of the approaches to decrease the costs …

Inflammation of the brain and the consequential immunological responses play pivotal roles
in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease …

Induced pluripotent stem cells (iPSCs) originate from the reprogramming of adult somatic
cells using four Yamanaka transcription factors. Since their discovery, the stem cell (SC) field …

Regenerative medicine has emerged as a novel alternative solution to organ failure which
circumvents the issue of organ shortage. In preclinical research settings bio-artificial organs …

Induced pluripotent stem cells (iPSCs) hold great potential to generate novel, curative cell
therapy products. However, current methods to generate these novel therapies lack …